pCPAO
pan-Canadian Pharmaceutical Alliance (pCPA): October 2020 Trends and Insights October 2020 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 5 new recommendations in October (22 files as of October 31). PRODUCT INDICATION SPONSOR Type REC’N* DATE Xtandi** (enzalutamide) Metastatic…
pan-Canadian Pharmaceutical Alliance (pCPA): September 2020 Trends and Insights September 2020 Highlights: 1 product completed CADTH review 0 products initiated pCPA negotiations 2 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 1 new recommendation in September (25 files as of September 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Zejula (niraparib) Ovarian…
pan-Canadian Pharmaceutical Alliance (pCPA): August 2020 Trends and Insights August 2020 Highlights: 2 products completed CADTH review 2 products initiated pCPA negotiations 1 negotiation was completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 2 new recommendations in August (25 files as of August 31). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Soliris (eculizumab) Neuromyelitis…
Toronto, September 9, 2020 – MORSE Consulting is pleased to announce that Sal Cimino has joined our team as Senior Consultant, Private Drug Plans. The private payer market is playing an increasingly important role in ensuring a product’s reimbursement success in Canada. With the introduction of new specialty biologics and gene therapies, private payers are turning to new cost containment strategies that strongly resemble the public payer market. Private payers…
pan-Canadian Pharmaceutical Alliance (pCPA): July 2020 Trends and Insights July 2020 Highlights: 6 products completed CADTH review 6 products initiated pCPA negotiations 7 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Trends are beginning to emerge regarding impact of COVID19 on pCPA negotiations with 3 months of experience to consider. In general, negotiations are taking longer to start…
pan-Canadian Pharmaceutical Alliance (pCPA): June 2020 Trends and Insights June Highlights: 4 products completed CADTH review 7 products initiated pCPA negotiations 4 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations in June (23 files as of June 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Cuvposa (glycopyrrolate) Chronic severe…
pan-Canadian Pharmaceutical Alliance (pCPA): May 2020 Trends and Insights May Highlights: 8 products completed CADTH review 5 products initiated pCPA negotiations 0 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation There was an evident slow down in May as the pCPA continues to adjust to the evolving COVID-19 situation. No negotiations were completed or closed for the first…
pan-Canadian Pharmaceutical Alliance (pCPA): April 2020 Trends and Insights April Highlights: 6 products completed CADTH review 4 products initiated pCPA negotiations 11 negotiations were completed with an LOI 2 negotiations were closed without an LOI 2 files were closed without negotiation In keeping with pCPA’s communication to industry associations, early trends into their management of files during the challenges associated with COVID indicate that initial priority has been on…
Toronto, April 27, 2020 – MORSE Consulting is pleased to release our April 2020 Update to the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. This 50+ PowerPoint report is aimed at assisting market access professionals plan for future launches and also serves as a valuable education tool for both internal and external stakeholders. What’s New in the April 2020 Update?…
pan-Canadian Pharmaceutical Alliance (pCPA): March 2020 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has launched a new website (https://www.pcpacanada.ca) with searchable data regarding brand name drug negotiations status and highlighting pCPA activity in the last four weeks. Highlights of the pCPA activity in March are: 5 products completed CADTH review, for a total of 16 files under consideration; 2 products initiated pCPA negotiations, for a total of 29…
pan-Canadian Pharmaceutical Alliance (pCPA): February 2020 Trends and Insights Due to the COVID-19 outbreak, the pCPA is implementing measures to work within the current reality while still attempting to meet its mandate. Consequently, some existing negotiations may be delayed or temporarily halted while the negotiating jurisdiction focuses on responding to the COVID-19 situation. The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the February 29, 2020 status of brand negotiations. Highlights…
Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns. Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system. Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an issue for all stakeholders. To help…
pan-Canadian Pharmaceutical Alliance (pCPA): January 2020 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the January 31, 2020 status of brand negotiations. Highlights since the last update include: ● 2 products completed CADTH review, for a total of 9 files under consideration; ● 4 products initiated pCPA negotiations, for a total of 34 active negotiations; ● 2 negotiations completed for a total of 297 completed negotiations; ●…
MORSE Consulting is pleased to release our Third Annual pCPA Year in Review infographic - 2019 Edition. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from 2019. This infographic compares year-over-year metrics including: pCPA activity summary; average time to complete a negotiation; files adjudicated by the pCPA; and average negotiation duration by source. This infographic is an excerpt from the 2019 update of MORSE Consulting’s Canadian Reimbursement Trends…
pan-Canadian Pharmaceutical Alliance (pCPA): December 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the December 31, 2019 status of brand negotiations. Highlights since the last update include: 3 products completed CADTH review, for a total of 10 files under consideration; 0 products initiated pCPA negotiations, for a total of 32 active negotiations; 1 negotiation completed for a total of 295 completed negotiations; 1 negotiation closed, for…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
pCPAO - Info and details on - Page 3 of 6 - MORSE Consulting Inc.
